An official website of the United States government
Home
Name
Liothyronine Sodium
Alternate Names
Basoprocin
Cynomel
Cyronine
Cytomel
Ibiothyron
L-Triiodothyronine
LT3
Tertroxin
Thyrolar
Triostat
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
NSC Number
80774
Primary Site
None
Histology
None
Remarks
Code Liothyronine Sodium as hormonal therapy in papillary, follicular or oncocytic thyroid carcinoma. Do not code if it is medullary or anaplastic thyroid carcinoma.
Rationale:
In papillary, follicular and oncocytic carcinoma Liothyronine Sodium has a dual role: 1. Suppression of TSH: This would be considered cancer directed therapy since the tumor cells of the above mentioned morphologies express TSH receptor. TSH is a trophic hormone that can promote tumor growth. 2. Hormonal replacement therapy to treat post-surgical or post-radiation hypothyroidism.
C-cells in medullary carcinoma do not express TSH receptor, thus, TSH suppression would not be indicated. However, replacement hormonal therapy with thyroid hormones (such as Liothyronine Sodium) post surgery is given to treat the post-surgical hypothyroidism. In operable thyroid anaplastic carcinoma the goal of thyroid hormones is hormone replacement.
Rationale:
In papillary, follicular and oncocytic carcinoma Liothyronine Sodium has a dual role: 1. Suppression of TSH: This would be considered cancer directed therapy since the tumor cells of the above mentioned morphologies express TSH receptor. TSH is a trophic hormone that can promote tumor growth. 2. Hormonal replacement therapy to treat post-surgical or post-radiation hypothyroidism.
C-cells in medullary carcinoma do not express TSH receptor, thus, TSH suppression would not be indicated. However, replacement hormonal therapy with thyroid hormones (such as Liothyronine Sodium) post surgery is given to treat the post-surgical hypothyroidism. In operable thyroid anaplastic carcinoma the goal of thyroid hormones is hormone replacement.
Coding
Please see remarks for additional information
